JP2023509462A5 - - Google Patents
Info
- Publication number
- JP2023509462A5 JP2023509462A5 JP2022541283A JP2022541283A JP2023509462A5 JP 2023509462 A5 JP2023509462 A5 JP 2023509462A5 JP 2022541283 A JP2022541283 A JP 2022541283A JP 2022541283 A JP2022541283 A JP 2022541283A JP 2023509462 A5 JP2023509462 A5 JP 2023509462A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- protein
- active site
- thioredoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025116559A JP2025182217A (ja) | 2020-01-03 | 2025-07-10 | チオレドキシン活性を有する組成物および関連方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062956994P | 2020-01-03 | 2020-01-03 | |
| US62/956,994 | 2020-01-03 | ||
| PCT/US2021/012109 WO2021138682A1 (en) | 2020-01-03 | 2021-01-04 | Compositions having thioredoxin activity and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116559A Division JP2025182217A (ja) | 2020-01-03 | 2025-07-10 | チオレドキシン活性を有する組成物および関連方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509462A JP2023509462A (ja) | 2023-03-08 |
| JP2023509462A5 true JP2023509462A5 (cg-RX-API-DMAC7.html) | 2024-08-27 |
Family
ID=76687128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541283A Pending JP2023509462A (ja) | 2020-01-03 | 2021-01-04 | チオレドキシン活性を有する組成物および関連方法 |
| JP2025116559A Pending JP2025182217A (ja) | 2020-01-03 | 2025-07-10 | チオレドキシン活性を有する組成物および関連方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116559A Pending JP2025182217A (ja) | 2020-01-03 | 2025-07-10 | チオレドキシン活性を有する組成物および関連方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230071765A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4084867A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023509462A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115315292A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163157A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021138682A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377653B (es) | 2013-03-15 | 2025-03-11 | Orpro Therapeutics Inc | Producto y uso para normalización de la viscoelasticidad del moco. |
| CA3187826A1 (en) * | 2020-06-23 | 2021-12-30 | Panasonic Intellectual Property Management Co., Ltd. | Allergen inactivation method and allergen inactivation device |
| CN119317716A (zh) * | 2022-07-05 | 2025-01-14 | 国立大学法人东北大学 | 抗病毒剂、用于治疗或者预防病毒感染症的药物组合物、病毒感染症的重症化风险的评价试剂盒以及病毒感染症的重症化风险的评价方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3515336C2 (de) * | 1985-04-27 | 1994-01-20 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Reinigung von â-Interferon |
| JPH10191977A (ja) * | 1997-01-14 | 1998-07-28 | Oriental Yeast Co Ltd | チオレドキシン改変体及び該改変体を含むap−1の転写活性能を増強する因子 |
| JP4758525B2 (ja) * | 1998-03-20 | 2011-08-31 | 武田薬品工業株式会社 | 生理活性ポリペプチドの徐放性製剤およびその製造法 |
| WO2004013283A2 (en) * | 2002-08-02 | 2004-02-12 | University Of Rochester | Thioredoxin mutants and uses thereof |
| WO2004087917A1 (ja) * | 2003-03-31 | 2004-10-14 | National Institute Of Advanced Industrial Science And Technology | チオレドキシン改変体 |
| US20090203586A1 (en) * | 2004-06-11 | 2009-08-13 | Syngenta Limited | Method for ameliorating an inflammatory skin condition |
| KR102374576B1 (ko) * | 2011-05-17 | 2022-03-15 | 솔리제닉스, 인크. | 열안정성 백신 조성물 및 그의 제조방법 |
| MX377653B (es) * | 2013-03-15 | 2025-03-11 | Orpro Therapeutics Inc | Producto y uso para normalización de la viscoelasticidad del moco. |
| WO2019222665A1 (en) * | 2018-05-17 | 2019-11-21 | Orpro Therapeutics, Inc. | Thiol-based multivalent drug delivery compositions |
-
2021
- 2021-01-04 WO PCT/US2021/012109 patent/WO2021138682A1/en not_active Ceased
- 2021-01-04 JP JP2022541283A patent/JP2023509462A/ja active Pending
- 2021-01-04 CA CA3163157A patent/CA3163157A1/en active Pending
- 2021-01-04 US US17/758,352 patent/US20230071765A1/en active Pending
- 2021-01-04 CN CN202180018760.3A patent/CN115315292A/zh active Pending
- 2021-01-04 EP EP21736199.7A patent/EP4084867A4/en active Pending
-
2025
- 2025-07-10 JP JP2025116559A patent/JP2025182217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7759693B2 (ja) | モンテルカストおよびペプチドの新規接合体 | |
| AU2002351181B2 (en) | Methods and compositions for treating lesions of the respiratory epithelium | |
| JP2024010006A5 (cg-RX-API-DMAC7.html) | ||
| US20090227511A1 (en) | Methods and compositions for treating lesions of the respiratory epithelium | |
| JP2022500437A5 (cg-RX-API-DMAC7.html) | ||
| JP2026000993A (ja) | 新ペプチド | |
| JP2024170583A5 (cg-RX-API-DMAC7.html) | ||
| JP2024504225A5 (cg-RX-API-DMAC7.html) | ||
| JP2023126658A5 (cg-RX-API-DMAC7.html) | ||
| CN106456707B (zh) | 干粉肽药剂 | |
| WO2024174948A1 (zh) | 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物 | |
| CN114533706B (zh) | 一种用于防治呼吸道疾病的雾化吸入制剂及其应用 | |
| US20240218016A1 (en) | Peptides and their use in the treatment of inflammation | |
| JP2016517446A5 (cg-RX-API-DMAC7.html) | ||
| US20120045479A1 (en) | Dry Powder Formulations, Vaccines and Methods | |
| Baugh et al. | Infectious croup: a critical review | |
| CN109200284B (zh) | 一种猪支原体肺炎活疫苗黏膜免疫佐剂、制备方法及其应用 | |
| TW202017939A (zh) | 貽貝黏著蛋白的抗病毒用途 | |
| JP2023524064A5 (cg-RX-API-DMAC7.html) | ||
| US20130281361A1 (en) | Methods of treating and preventing rhinovirus infection | |
| Mäkelä et al. | Treatment of respiratory syncytial virus infections in children | |
| HUT75660A (en) | Novel remedy for respiratory-tract viral disease | |
| JP2023517480A5 (cg-RX-API-DMAC7.html) | ||
| PRIGAL | Studies with Medicated Aerosols: The Use of the Lungs as a Portal for the Introduction of Therapeutic Agents for Systemic Effect | |
| Busey et al. | The Treatment of Cystic Fibrosis: A Statement by the Committee on Therapy |